Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.63 |
| ▸ | GLS | O94925 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13166754 | 0.87 | RIPK1 (0.52) | RIPK1GLSHTR2CSLC6A4PYCR1 | |
| SCHEMBL7021352 | 0.87 | GLS (0.53) | RIPK1GLSHTR2CSLC6A4CTSB | |
| SCHEMBL4398498 | 0.87 | RIPK1 (0.53) | RIPK1PYCR1PTGESCTSBCTSS | |
| SCHEMBL3012881 | 0.86 | TAAR1 (0.55) | RIPK1GLSHTR2CSLC6A4CTSB | |
| SCHEMBL22771190 | 0.85 | RIPK1 (0.43) | RIPK1GLSHTR2CSLC6A4CTSB | |
| SCHEMBL30264842 | 0.84 | HSP90AA1 (0.49) | RIPK1GLSHTR2CSLC6A4CTSB | |
| SCHEMBL16942777 | 0.84 | HSD17B2 (0.53) | RIPK1GLSHTR2CSLC6A4 | |
| SCHEMBL14426297 | 0.84 | HSP90AA1 (0.49) | RIPK1GLSHTR2CSLC6A4CTSB | |
| SCHEMBL1831339 | 0.84 | GLS (0.50) | RIPK1GLSHTR2CSLC6A4CTSB | |
| SCHEMBL24387236 | 0.83 | RIPK1 (0.53) | RIPK1PYCR1PTGESCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688779-A2 | NOVEL COMPOUNDS AND USES THEREOF | Acelink Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2025-09-25 | — | — | US | disclosed |
| WO-2024211244-A2 | NOVEL COMPOUNDS AND USES THEREOF | ACELINK THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20230322776-A1 | NEW ARYL-PYRIDO-PYRIMIDIN-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-10-12 | — | — | US | disclosed |
| EP-3643308-B1 | COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF | CSTONE PHARMACEUTICALS (KY) | 2021-05-19 | — | — | EP | disclosed |
| EP-3643308-A1 | COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF | CSTONE PHARMACEUTICALS (KY) | 2020-04-29 | — | — | EP | disclosed |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| US-8969356-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-03 | — | — | US | disclosed |
| CN-1950335-A | Novel biaromatic compounds which activate PPAR.gamma.-type receptors, their process of preparation and their use in cosmetic or pharmaceutical compositions | GALDERMA RES & DEV (FR) | 2007-04-18 | — | — | CN | disclosed |
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20060270654-A1 | 1,6-Dihydro-1,3,5,6-Tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-30 | — | — | US | disclosed |
| WO-2006122137-A1 | 1, 6 -DIHYDRO- 1,3, 5, 6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS INHIBITORS OF IKK ENZYME ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-16 | — | — | WO | disclosed |
| CN-1723193-A | Novel polycyclic compounds which modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RES & DEV (FR) | 2006-01-18 | — | — | CN | disclosed |
| CN-1639138-A | Biphenylmethyl-thiazolidinediones and analogues and their use as PPAR-gamma activators | GALDERMA RES & DEV (FR) | 2005-07-13 | — | — | CN | disclosed |
| CN-1468226-A | Biphenyl derivatives and their use as ppar-gamma receptor activators | �������о�����չ˽������˾ | 2004-01-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | RIPK1 4081/4885GLS 2132/4885HTR2C 4542/4885 |
| US-20230322776-A1 | NEW ARYL-PYRIDO-PYRIMIDIN-ONE DERIVATIVES | QDPR, P2RY1, REN | RIPK1 4270/4885GLS 645/4885HTR2C 228/4885 |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | RIPK1 2026/4885GLS 140/4885HTR2C 4268/4885 |
| US-20060270654-A1 | 1,6-Dihydro-1,3,5,6-Tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | IL1R1, IDO1, TLR1 | RIPK1 779/4885GLS 4062/4885HTR2C 1556/4885 |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | CFD, CFH, CFB | RIPK1 4791/4885GLS 825/4885HTR2C 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.